SCHEMBL2968217

SCHEMBL2968217

COc1cc2c(cc1S(=O)(=O)Nc1nnc(C(C)C)s1)CC(N)C2

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.50
HSD17B10 Q99714 2/20 0.50
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 5/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
KDM4E B2RXH2 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
G6PD P11413 1/20 0.35
POLB P06746 2/20 0.35
MAPT P10636 2/20 0.35
TSHR P16473 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GLA P06280 1/20 0.35
AMY1A P0DUB6 1/20 0.35
HPGD P15428 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2962997 0.85 ALDH1A1 (0.44) ALDH1A1HSD17B10SMN1; SMN2NPC1RAB9A
SCHEMBL2960594 0.79 ALDH1A1 (0.56) ALDH1A1HSD17B10LMNACA1CA2
SCHEMBL2968210 0.79 LMNA (0.46) ALDH1A1HSD17B10LMNASMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL1968225 0.78 ALDH1A1 (0.55) ALDH1A1HSD17B10LMNACA1CA2
SCHEMBL294581 0.76 LMNA (0.40) ALDH1A1HSD17B10LMNASMN1; SMN2RAB9A
SCHEMBL5397717 0.76 ALDH1A1 (0.57) ALDH1A1HSD17B10LMNASMN1; SMN2KDM4E
SCHEMBL1969717 0.74 ALDH1A1 (0.39) ALDH1A1HSD17B10LMNASMN1; SMN2NPC1
SCHEMBL12585459 0.74 ALDH1A1 (0.52) ALDH1A1HSD17B10LMNACA1CA2
SCHEMBL1970540 0.73 ALDH1A1 (0.41) ALDH1A1HSD17B10LMNASMN1; SMN2NPC1
SCHEMBL3048704 0.68 CA1 (0.49) ALDH1A1LMNACA1CA2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772257-B2 Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use SANOFI-AVENTIS (FR) 2010-08-10 US disclosed
US-20100022603-A1 BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE SANOFI-AVENTIS (FR) 2010-01-28 US disclosed
US-7612104-B2 Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use SANOFI-AVENTIS (FR) 2009-11-03 US disclosed
US-20080293780-A1 BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE SANOFI-AVENTIS (FR) 2008-11-27 US disclosed
EP-1937675-A2 BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-07-02 EP disclosed
WO-2007039174-A2 BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293780-A1 BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE PPARG, PPARA, PPARD ALDH1A1 1019/4885HSD17B10 617/4885LMNA 2553/4885
US-20100022603-A1 BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE PPARG, PPARA, PPARD ALDH1A1 1072/4885HSD17B10 622/4885LMNA 2614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.